A compound of Formula: wherein: R 1 is -(CR a R b) m -aryl, -CH=CH-aryl, -(CR c R d) n -heteroaryl, -(CR e R f) o -heterocycloalkyl, or -(CR g R h) p -cycloalkyl; m, n, o, and p are each independently 0, 1, or 2; R a, R b, R c, R d, R e, R f, R g, and R h are each independently H, halo, or C 1-4 alkyl, or R a and R b are taken together with the carbon to which they are attached to form a cycloalkyl ring, or R a and R b are taken together to form =CH 2 or =O; each aryl, heteroaryl, heterocycloalkyl, or cycloalkyl present in R 1 is unsubstituted or substituted with one or two R x substituents; wherein each R x substituent is independently halo, C 1-4 alkyl, cycloalkyl, -C 1-2 -haloalkyl, -OH, -OC 1-4 alkyl, -O-C 1-2 -haloalkyl, cyano, -C C 1-4 alkyl, -C NR i R j, -SO 2 C 1-4 alkyl, -SO 2 NR k R l, -NR q R r, -C -cycloalkyl, -C -aryl (optionally substituted with methyl or halo), -CO 2 C 1-4 alkyl, -CO 2 aryl, -C CH 2 -aryl (optionally substituted with methyl or halo), -CH 2 -aryl (optionally substituted with methyl or halo), or monocyclic heterocycloalkyl (optionally substituted with methyl, -C C 1-4 alkyl, or -CO 2 C 1-4 alkyl); wherein R i, R j, R k, and R l are each independently H, C 1-4 alkyl, -C 1-4 alkyl-OH, or -C 1-4 alkyl-O-C 1-4 alkyl, wherein R q and R r are each independently H, C 1-4 alkyl, -C 1-4 alkyl-OH, -C 1-4 alkyl-O-C 1-4 alkyl, -C C 1-4 alkyl, -CO 2 C 1-4 alkyl, or -SO 2 C 1-4 alkyl; L is -S 2 -; X is O, S, NH, N(CO 2 C 1-4 alkyl), N(SO 2 C 1-4 alkyl), N(SO 2 cycloalkyl), or CH 2; Y 1, Y 2, and Y 3 are each independently CH or N; G 2 is N or CR 2; G 3 is N or CR 3; G 4 is N, NR 4b, or CR 4a; G 5 is N or CR 5; and G 6 is N or CR 6; wherein R 2, R 3, R 4a, R 5, and R 6 are each independently hydrogen, halogen, -OH, -alkyl, -Oalkyl, -haloalkyl, -O-haloalkyl, or -NR u R v; or R 4b is taken together with R 6 and the atoms to which they are attached to form a heteroaryl or heterocyclic ring; wherein the heteroaryl ring comprising R 4b and R 6 comprises no more than one N and is optionally substituted with alkyl, and the heterocyclic ring comprising R 4b and R 6 is optionally substituted with oxo, R u is H or C 1-4 alkyl; R v is H, C 1-4 alkyl, monocyclic cycloalkyl, -C C 1-4 alkyl, or -C NR w R y; wherein each alkyl present in R v is unsubstituted or substituted with -OH, -NH 2, -NH(C 1-4 alkyl), or -N(C 1-4 alkyl) 2, R w and R y are each independently H or C 1-4 alkyl; wherein is not unsubstituted phenyl; and R 7 and R 8 are each independently hydrogen or C 1-4 alkyl, or R 7 and R 8 are taken together to form -CH 2 CH 2 -; or a pharmaceutically acceptable salt thereof. R 1 is -(CR a R b) m -aryl, -CH=CH-aryl, -(CR c R d) n -heteroaryl, -(CR e R f) o -heterocycloalkyl, or -(CR g R h) p -cycloalkyl; m, n, o, and p are each independently 0, 1, or 2; R a, R b, R c, R d, R e, R f, R g, and R h are each independently H, halo, or C 1-4 alkyl, or R a and R b are taken together with the carbon to which they are attached to form a cycloalkyl ring, or R a and R b are taken together to form =CH 2 or =O; each aryl, heteroaryl, heterocycloalkyl, or cycloalkyl present in R 1 is unsubstituted or substituted with one or two R x substituents; wherein each R x substituent is independently halo, C 1-4 alkyl, cycloalkyl, -C 1-2 -haloalkyl, -OH, -OC 1-4 alkyl, -O-C 1-2 -haloalkyl, cyano, -C C 1-4 alkyl, -C NR i R j, -SO 2 C 1-4 alkyl, -SO 2 NR k R l, -NR q R r, -C -cycloalkyl, -C -aryl (optionally substituted with methyl or halo), -CO 2 C 1-4 alkyl, -CO 2 aryl, -C CH 2 -aryl (optionally substituted with methyl or halo), -CH 2 -aryl (optionally substituted with methyl or halo), or monocyclic heterocycloalkyl (optionally substituted with methyl, -C C 1-4 alkyl, or -CO 2 C 1-4 alkyl); wherein R i, R j, R k, and R l are each independently H, C 1-4 alkyl, -C 1-4 alkyl-OH, or -C 1-4 alkyl-O-C 1-4 alkyl, wherein R q and R r are each independently H, C 1-4 alkyl, -C 1-4 alkyl-OH, -C 1-4 alkyl-O-C 1-4 alkyl, -C C 1-4 alkyl, -CO 2 C 1-4 alkyl, or -SO 2 C 1-4 alkyl; L is -S 2 -; X is O, S, NH, N(CO 2 C 1-4 alkyl), N(SO 2 C 1-4 alkyl), N(SO 2 cycloalkyl), or CH 2; Y 1, Y 2, and Y 3 are each independently CH or N; G 2 is N or CR 2; G 3 is N or CR 3; G 4 is N, NR 4b, or CR 4a; G 5 is N or CR 5; and G 6 is N or CR 6; wherein R 2, R 3, R 4a, R 5, and R 6 are each independently hydrogen, halogen, -OH, -alkyl, -Oalkyl, -haloalkyl, -O-haloalkyl, or -NR u R v; or R 4b is taken together with R 6 and the atoms to which they are attached to form a heteroaryl or heterocyclic ring; wherein the heteroaryl ring comprising R 4b and R 6 comprises no more than one N and is optionally substituted with alkyl, and the heterocyclic ring comprising R 4b and R 6 is optionally substituted with oxo, R u is H or C 1-4 alkyl; R v is H, C 1-4 alkyl, monocyclic cycloalkyl, -C C 1-4 alkyl, or -C NR w R y; wherein each alkyl present in R v is unsubstituted or substituted with -OH, -NH 2, -NH(C 1-4 alkyl), or -N(C 1-4 alkyl) 2, R w and R y are each independently H or C 1-4 alkyl; wherein is not unsubstituted phenyl; and R 7 and R 8 are each independently hydrogen or C 1-4 alkyl, or R 7 and R 8 are taken together to form -CH 2 CH 2 -; or a pharmaceutically acceptable salt thereof.